Tissue Regenix proposes acquisition of CellRight Technologies: 4 notes

Megan Wood -   Print  |

Tissue Regenix reported a proposed acquisition of CellRight Technologies.

Here are four notes:


1. CellRight Technologies boasts an orthopedic portfolio with human-derived bone graft products.


2. Tissue Regenix develops soft tissue products featuring its patented decellularisation dCELL Technology.


3. Tissue Regenix would leverage CellRight Technologies' San Antonio-based tissue bank, opening a door to the U.S. market.


4. The proposed acquisition would allow Tissue Regenix to enter the U.S. orthopedics market by 2018, honing in on ligament reconstruction.


More articles on devices:
Spinal cord stimulation market to grow at a 9.2% CAGR through 2021 — 5 observations
4 key notes on Stryker mid-year
Dr. Steven DeLuca performs 1st surgery in Premia Spine's FDA pivotal study: 5 key notes

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers